The capital is pricing Alzheimer's prevention. The phase 3 data from Eisai and Biogen's lecanemab extension study (CLARITY AD open-label, n=1,795, 36-month amyloid PET endpoint) shows statistically significant plaque clearance but a CDR-SB functional decline of 27% versus placebo -- a number the original trial's 0.45-point difference on an 18-point scale had already telegraphed as modest. Family-office positions across Singapore and Hong Kong priced the asset as a prevention play on APOE-e4 carriers; what the extension data shows is a disease-modification signal in a population already symptomatic, which is a different asset with a different total addressable market and a different payer structure under MOH Singapore's rare-disease-funding framework and Australia's TGA Advisory Committee on Medicines, which declined reimbursement recommendation in March 2026 citing uncertain clinical meaningfulness against the 3% incidence of ARIA-E (amyloid-related imaging abnormalities, edema subtype).

The two-ledger divergence is now structural. The capital priced a prevention market -- the presymptomatic APOE-e4 screen-and-treat model that Eisai's investor materials have described since 2023, a market requiring population-level amyloid PET access that does not exist at scale in any APAC jurisdiction. The trial delivered a treatment signal in a diagnosed population, with an adverse-event rate that NMPA's Center for Drug Evaluation cited in its January 2026 conditional approval notice as the reason for the restricted-use designation: hospital-based infusion only, MRI surveillance at weeks 4 and 8, and exclusion of anticoagulated patients. My read is that the APAC capital allocating to the prevention thesis is holding a clinical instrument the regulators have not approved for the population the capital assumes. The next observable signal is TGA's Advisory Committee reconvening date, currently scheduled for Q3 2026, at which Eisai's re-submission will test whether the 36-month functional data shifts the committee's March verdict on clinical meaningfulness.